MAP2K1 and melanoma: We previously reported the outcomes of the multicentre Phase II DOC-MEK trial for patients with advanced BRAF wild-type melanoma.13 Patients were randomised to treatment with docetaxel plus either MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) or placebo.